Floatz logo

Maplirpacept

Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Mayo ClinicPhase 2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

107 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Ifosfamide
University of California, Davis
Phase 3BB
Cyclophosphamide
Nathan Denlinger
Phase 3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Maplirpacept is also rated in:

diffuse large B-cell lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →
ALK-positive large B-cell lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →